CMP-001 + Pembrolizumab for Lymphoma

Overseen By Umar Farooq, MD

Age: 18+

Sex: Any

Trial Phase: Phase 1 & 2

Sponsor: Umar Farooq

Must not be taking: Anti-PD-1, Anti-PD-L1

Disqualifiers: Active infection, HIV, Hepatitis B, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

Duration: Up to 2 years

14 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This study is a single-arm, open-label, phase I/II trial designed to find a CMP-001 dose that, in combination with pembrolizumab, has optimal clinical efficacy and acceptable toxicity for patients with relapsed and refractory lymphomas.

Who Is on the Research Team?

Umar Farooq, MD

Principal Investigator

University of Iowa

Are You a Good Fit for This Trial?

Adults with relapsed or refractory Hodgkin or Non-Hodgkin Lymphoma who've had prior B cell therapy are eligible. They must have measurable disease, be in good physical condition (ECOG 0-1), and agree to use contraception. Exclusions include lung disease requiring steroids, certain psychiatric/substance abuse disorders, recent other cancer treatments, live vaccines within a month, active infections like Hepatitis/HIV, autoimmune diseases treated within two years.

Inclusion Criteria

My cancer can be measured and has grown in previously treated areas.

I have given my written consent to participate and can follow the study's requirements.

I have had B cell therapy but my B cell count is sufficient or I've responded well to a test vaccine.

Exclusion Criteria

I have not received a live vaccine within the last 30 days.

- Hematological: Absolute neutrophil count (ANC) ≥1000/µL;Platelets ≥75 000/µL; Hemoglobin ≥8.0 g/dLa;

My organ function is not within the required range for the study.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive intratumoral administration of CMP-001 and intravenous administration of pembrolizumab

Up to 2 years

Follow-up

Participants are monitored for safety and effectiveness after treatment

6 months

What Are the Treatments Tested in This Trial?

Interventions

• CMP-001
• Pembrolizumab

Trial Overview The trial is testing CMP-001 combined with pembrolizumab for lymphoma patients who haven't responded well to previous treatments. It's an early phase trial aiming to find the right dose that works best while keeping side effects manageable.

How Is the Trial Designed?

Group I: CMP-001 plus pembrolizumab Experimental Treatment 2 Interventions

Intratumoral administration of CMP-001 and intravenous administration of pembrolizumab

Who Is Running the Clinical Trial?

Umar Farooq

Lead Sponsor

Trials

1

Recruited

40+

Merck Sharp & Dohme LLC

Industry Sponsor

Trials

4,096

Recruited

5,232,000+

Chirfi Guindo

Merck Sharp & Dohme LLC

Chief Marketing Officer since 2022

Degree in Engineering from Ecole Centrale de Paris, MBA from New York University Stern School of Business

Robert M. Davis

Merck Sharp & Dohme LLC

Chief Executive Officer since 2021

JD from Northwestern University Pritzker School of Law, MBA from Northwestern University Kellogg Graduate School of Management, Bachelor's in Finance from Miami University

University of Iowa

Collaborator

Trials

486

Recruited

934,000+

Checkmate Pharmaceuticals

Industry Sponsor

Trials

11

Recruited

520+